Uremic hyperhomocysteinemia: A randomized trial of folate treatment for the prevention of cardiovascular events

Hemodialysis International

Volumn 11, Issue 2, 2007, Pages 210-216

  Vianna, Areuza C A ^a   Mocelin, Altair J ^a   Matsuo, Tiemi ^a   Morais Filho, Domingos ^a   Largura, Alvaro ^b   Delfino, Vinicius A ^a   Soares, Abel E ^a   Matni, Anuar M ^a  

^a STATE UNIVERSITY OF LONDRINA   (Brazil)

^b Cascavel State University   (Brazil)

Author keywords

Cardiovascular events; Carotidwall thickness; Chronic uremia; Folicacid; Homocysteine

Indexed keywords

FOLIC ACID; HOMOCYSTEINE; PLACEBO;

ADULT; ANGINA PECTORIS; ARTERIOGRAPHY; ARTERY INTIMA PROLIFERATION; ARTICLE; CARDIOVASCULAR DISEASE; CAROTID ARTERY DISEASE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DOUBLE BLIND PROCEDURE; FATALITY; FEMALE; HAZARD RATIO; HEART ARRHYTHMIA; HEART FAILURE; HEART INFARCTION; HEMODIALYSIS; HOSPITAL ADMISSION; HUMAN; HYPERHOMOCYSTEINEMIA; INCIDENCE; KAPLAN MEIER METHOD; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; UREMIA;

ADULT; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; DOUBLE-BLIND METHOD; FEMALE; FOLIC ACID; HUMANS; HYPERHOMOCYSTEINEMIA; MALE; MIDDLE AGED; SURVIVAL RATE; TREATMENT OUTCOME; UREMIA;

EID: 34047213098     PISSN: 14927535     EISSN: 15424758     Source Type: Journal    
DOI: 10.1111/j.1542-4758.2007.00171.x     Document Type: Article

References (21)

1. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005; 352: 1685-1695.
2. Eknoyan G. Meeting the challenges of the new K/DOQI guidelines. Am J Kidney Dis. 2003; 41: S3-S10.
3. McCully KS. Vascular pathology of homocysteinemia: Implications for the pathogenesis of arteriosclerosis. Am J Pathol. 1969; 56: 111-128.
4. Clark R, Daly L, Robinson K, et al. Hyperhomocysteinemia: An independent risk factor for vascular disease. N Engl J Med. 1991; 324: 1149-1155.
5. Seshadri N, Robinson K. Homocysteine, B vitamins, and coronary artery disease. Med Clin North Am. 2000; 84: 215-237.
6. Stampfer MJ, Malinow MR, Willet WC, et al. A prospective study of plasma homocysteine and risk of myocardial infarction in US physicians. JAMA. 1992; 268: 877-881.
7. Moustapha A, Naso A, Nahlavi M, et al. Prospective study of hyperhomocysteinemia as an adverse cardiovascular risk factor in end-stage renal disease. Circulation. 1998; 97: 138-141.
8. Gonin JM. Folic acid supplementation to prevent adverse events in individuals with chronic renal disease and end-stage renal disease. Curr Opin Nephrol Hypertens. 2005; 14: 277-281.
9. Bostom AG, Shemin D, Lapane KL, et al. Hyperhomocysteinemia and traditional cardiovascular disease risk factors in end-stage renal disease patients on dialysis: A case-control study. Atherosclerosis. 1995; 114: 93-103.
10. Gonin JM, Nguyen H, Gonin R, et al. Controlled trials of very high dose folic acid, vitamin B12 and B6, intravenous folinic acid and serine for treatment of hyperhomocysteinemia in ESRD. J Nephrol. 2003; 16: 522-534.
11. Kato A, Takako I, Yukitara T, Maruyama Y, Kumagal H, Hishida A. Impact of carotid atherosclerosis on long-term mortality in chronic hemodialysis patients. Kidney Int. 2003; 64: 1472-1479.
12. Araki A, Sako Y. Determination of free and total homocysteine in human plasma by high-performance liquid chromatography with fluorescence detection. J Chromatogr. 1987; 422: 43-52.
13. Boston AG, Lathrop L. Hyperhomocysteinemia in end-stage renal disease: Prevalence, etiology, and potential relationship to arteriosclerotic outcomes. Kidney Int. 1997; 52: 10-20.
14. Salonen JT. Precision and reproducibility of ultrasonographic measurement of progression of common carotid artery atherosclerosis. Lancet. 1993; 341: 1158-1159.
15. Cunningham J, Sharman VL, Goodwin FJ, March FP. Do patients receiving hemodialysis need folic acid supplements? Br Med J (Clin Res Educ). 1981; 282: 1582.
16. Romao JEJ. Doenca Renal Cronica: Definicao, epidemiologia e classificacao. J Bras Nefrol. 2004; 26: 1-3.
17. Rabelink TJ. Cardiovascular risk in patients with renal disease: Treating the risk or treating the risk factor? Nephrol Dial Transplant. 2004; 19: 23-26.
18. Law MR, Wald NJ. Education and debate. Risk factor thresholds: Their existence under scrutiny. Br Med J. 2002; 324: 1570-1576.
19. Bennett-Richards K, Kattenhorn M, Donald A, et al. Does oral folic acid lower total homocysteine levels and improve endothelial function in children with chronic renal failure? Circulation. 2002; 105: 1810-1815.
20. Schnyder G, Roffi M, Pin R, et al. Decreased rate of coronary restenosis after lowering of plasma homocysteine levels. N Engl J Med. 2001; 345: 1593-1600.
21. Marcucci R, Zanazzi M, Bertoni E, et al. Vitamin supplementation reduces the progression of atherosclerosis in hyperhomocysteinemic renal transplant recipients. Transplantation. 2003; 75: 1551-1555.